Clinical Trials Browser

Phase 3 × Active not recruiting × Sarcoma × Clear all

NCT03914612 2026-04-21

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Phase 3 Active not recruiting

813 enrolled 16 charts 2 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT02306161 2026-04-13

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Phase 3 Active not recruiting

312 enrolled 14 charts

Sarcoma, Ewing

NCT02567435 2026-04-13

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

Phase 3 Active not recruiting

325 enrolled 14 charts

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT04214067 2026-04-13

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

Phase 3 Active not recruiting

Carcinosarcoma

NCT06935409 2026-04-09

Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure

Phase 3 Active not recruiting

Osteosarcoma

NCT05095376 2026-04-03

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

Phase 3 Active not recruiting

Glioblastoma, Gliosarcoma

NCT04994132 2026-02-17

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

Phase 3 Active not recruiting

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT03673501 2026-02-05

INTRIGUE

Phase 3 Active not recruiting

453 enrolled 20 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT05208047 2026-02-04

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Phase 3 Active not recruiting

GastrointestinalSarcoma

Neoplasm Metastasis, Gastrointestinal Stromal Tumors

NCT05734105 2025-12-17

INSIGHT

Phase 3 Active not recruiting

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT03784014 2025-12-11

MULTISARC

Phase 3 Active not recruiting

Neoplasm Metastasis, Sarcoma

NCT01371981 2025-11-26

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 3 Active not recruiting

1,645 enrolled 32 charts

Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT01223248 2025-11-04

Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy

Phase 3 Active not recruiting

DermatologicGynecologicSarcoma

Melanoma, Ovarian Neoplasms, Sarcoma, Pyloric Stenosis, Hypertrophic

NCT06263231 2025-07-29

INVINCIBLE-3

Phase 3 Active not recruiting

Sarcoma

NCT00470223 2025-06-08

OS2006

Phase 3 Active not recruiting

Sarcoma, Osteosarcoma

NCT05115331 2025-05-31

1-2 PUNCH

Phase 3 Active not recruiting

Bone Diseases, Bone Neoplasms

NCT02413736 2025-03-12

Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST

Phase 3 Active not recruiting

Sarcoma

NCT02565498 2024-02-20

Preoperative vs Postoperative IMRT for Extremity/Truncal STS

Phase 3 Active not recruiting

Sarcoma